Skip to content

Opko Health OPK Royalty — Effect On Future Earnings Offset Amount

Similar metrics at other companies

Xencor logo
XNCRRoyalties — Expected royalty interest payments
$12M
Collegium Pharmaceutical, Inc. logo
COLLDeferred royalty obligation
$121.63M+0.1%
BioCryst Pharmaceuticals logo
BCRXRoyalty revenues payable
-$31.48M-19.6%
Ondas, Inc.
 logo
ONDSRoyalty Expense
$85.5K+23.5%
Falcon's Beyond Global logo
FBYDRoyalty Expense
$25K0.0%
Syndax Pharmaceuticals logo
SNDXRoyalty expense
$11.85M+47.2%

Other financials

Income statement

See full
Revenue$124.2M-17.2%
Gross profit$45.8M+7.4%
Operating income-$51.0M+24.0%
Net income-$54.8M+18.9%
EPS (diluted)-$0.07+30.0%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$52.8M-4.2%
Total equity$1.2B-8.2%
Total assets$1.9B-12.8%

Cash flow

See full
Operating cash flow-$19.3M+44.1%
CapEx$1.8M-42.6%
Free cash flow-$21.1M+44.0%

Valuation

See full
Market cap$1.13B+10.0%
P/S1.9×+0.5×

Profitability

See full
Gross margin36%+4.2pp
Operating margin-17.4%-5.6pp
Net margin-36.6%-44.8pp
FCF margin-30%+0.1pp

Returns & leverage

See full
Return on equity-16.9%-21.7pp
Debt / equity0.0×
Current ratio3.6×+1.1×

Where this comes from

Reported directly by Opko Health in its filing.

Tagged under the XBRL concept us-gaap:EffectOnFutureEarningsOffsetAmount.

The official record: Opko Health’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opko Health's royalty — effect on future earnings offset amount.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opko Health's royalty — effect on future earnings offset amount?
Opko Health (OPK) reported royalty — effect on future earnings offset amount of $6.4M in Q1 2026.
What does royalty — effect on future earnings offset amount mean?
This metric represents the financial adjustment or contra-revenue amount applied to offset future earnings derived from royalty-based intellectual property agreements. It reflects the accounting mechanism used to reconcile upfront payments or milestone credits against ongoing royalty streams. Investors use this to assess the net cash flow impact of long-term licensing arrangements and the sustainability of royalty-derived income.